Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$11.94 +0.3%	$10.64	$7.80 ▼ $28.09	$649.84M	N/A	304,823 shs	189,264 shs
CLYM Climb Bio	$2.23 -3.0%	$1.61	$1.05 ▼ $8.79	$155.86M	-0.11	878,948 shs	288,883 shs
MGTX MeiraGTx	$7.30 -2.5%	$7.80	$3.85 ▼ $8.98	$602.55M	1.25	335,274 shs	242,016 shs
VIR Vir Biotechnology	$4.94 -2.0%	$5.09	$4.16 ▼ $14.45	$700.14M	1.18	1.50 million shs	1.68 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	+0.25%	+0.84%	+2.93%	+28.66%	+1,193,999,900.00%
CLYM Climb Bio	-3.04%	-6.30%	+46.71%	+84.30%	+222,999,900.00%
MGTX MeiraGTx	-2.54%	-6.77%	-7.48%	+40.93%	+77.62%
VIR Vir Biotechnology	-1.98%	+7.86%	-5.73%	+1.65%	-40.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	1.8146 of 5 stars	3.5	0.0	0.0	1.8	0.8	0.6
CLYM Climb Bio	3.3298 of 5 stars	3.7	0.0	0.0	3.3	2.5	1.3
MGTX MeiraGTx	4.5652 of 5 stars	3.5	4.0	4.8	3.2	2.5	0.6
VIR Vir Biotechnology	3.3216 of 5 stars	3.4	2.0	0.0	3.3	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$32.25	170.11% Upside
CLYM Climb Bio	3.33	Buy	$9.00	303.59% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	228.77% Upside
VIR Vir Biotechnology	2.89	Moderate Buy	$28.44	475.80% Upside

Current Analyst Ratings Breakdown

Latest CLYM, MGTX, VIR, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	VIR Vir Biotechnology	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$12.00 ➝ $14.00
8/22/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
8/18/2025	BCAX Bicara Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$36.00
8/15/2025	CLYM Climb Bio	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/15/2025	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
8/15/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
8/12/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$2.74 per share	N/A
MGTX MeiraGTx	$33.28M	17.65	N/A	N/A	$0.04 per share	182.50
VIR Vir Biotechnology	$74.21M	9.25	N/A	N/A	$6.82 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	-$3.17	N/A	N/A	N/A	N/A	-21.67%	-20.89%	11/11/2025 (Estimated)
CLYM Climb Bio	-$73.90M	-$0.70	N/A	N/A	N/A	N/A	-23.10%	-22.47%	11/11/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.04	N/A	19.21	N/A	-415.39%	-314.44%	-63.28%	11/12/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.00	N/A	N/A	N/A	-2,895.94%	-50.22%	-40.78%	10/30/2025 (Estimated)

Latest CLYM, MGTX, VIR, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MGTX MeiraGTx	-$0.52	-$0.48	+$0.04	-$0.48	$8.00 million	$3.69 million
8/12/2025	Q2 2025	BCAX Bicara Therapeutics	-$0.54	-$0.50	+$0.04	-$0.50	N/A	N/A
8/12/2025	Q2 2025	CLYM Climb Bio	-$0.19	-$0.13	+$0.06	-$0.13	N/A	N/A
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.72	-$0.80	-$0.08	-$0.80	$2.38 million	$1.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	25.80	25.80
CLYM Climb Bio	N/A	14.08	14.08
MGTX MeiraGTx	26.29	0.88	0.88
VIR Vir Biotechnology	N/A	7.01	7.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
CLYM Climb Bio	69.76%
MGTX MeiraGTx	67.48%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
CLYM Climb Bio	0.80%
MGTX MeiraGTx	7.50%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.56 million	46.11 million	N/A
CLYM Climb Bio	9	67.76 million	67.22 million	N/A
MGTX MeiraGTx	300	80.45 million	74.41 million	Optionable
VIR Vir Biotechnology	580	138.92 million	116.69 million	Optionable

CLYM, MGTX, VIR, and BCAX Headlines

Recent News About These Companies

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up Following Analyst Upgrade

August 29 at 10:45 AM | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Rating Increased to Buy at Bank of America

August 29 at 8:30 AM | marketbeat.com

Bank of America Upgrades Vir Biotechnology (NASDAQ:VIR) to Buy

August 29 at 2:39 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up After Analyst Upgrade

August 29 at 2:13 AM | americanbankingnews.com

Vir Biotechnology stock soars after BofA upgrade, $14 target

August 28 at 9:14 PM | investing.com

Vir Stock Soars After BofA Boosts Rating on Liver Therapy

August 28 at 9:14 PM | finance.yahoo.com

Vir upgraded at BoA on potential for liver disease asset; shares surge 13%

August 28 at 9:14 PM | msn.com

Vir Biotechnology, Inc. $VIR Shares Bought by Charles Schwab Investment Management Inc.

August 28 at 3:13 AM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

August 28 at 3:10 AM | marketbeat.com

Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls

August 27 at 10:51 AM | finance.yahoo.com

BofA upgrades Vir Biotechnology to Buy on underappreciated HDV opportunity

August 27 at 10:51 AM | msn.com

Vir Biotechnology upgraded to Buy from Neutral at BofA

August 27 at 10:51 AM | msn.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Analysts

August 26, 2025 | americanbankingnews.com

Vanguard Group Inc. Sells 323,127 Shares of Vir Biotechnology, Inc. $VIR

August 26, 2025 | marketbeat.com

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 25, 2025 | businesswire.com

Aberdeen Group plc Acquires 330,031 Shares of Vir Biotechnology, Inc. $VIR

August 23, 2025 | marketbeat.com

Vir Biotechnology, Inc. $VIR Shares Bought by Public Sector Pension Investment Board

August 23, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for VIR Earnings

August 12, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month Low - Here's Why

August 10, 2025 | marketbeat.com

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLYM, MGTX, VIR, and BCAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$11.94 +0.03 (+0.25%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$11.93 -0.01 (-0.08%)

As of 08/29/2025 04:20 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Climb Bio NASDAQ:CLYM

$2.23 -0.07 (-3.04%)

As of 08/29/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

MeiraGTx NASDAQ:MGTX

$7.30 -0.19 (-2.54%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.30 0.00 (0.00%)

As of 08/29/2025 04:20 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Vir Biotechnology NASDAQ:VIR

$4.94 -0.10 (-1.98%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.98 +0.04 (+0.81%)

As of 08/29/2025 07:57 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time